Gan & Lee and Menarini Advance Bofanglutide in Europe
Beijing, China & Florence, Italy, September 3, 2026 Gan & Lee Pharmaceuticals and The Menarini Group have entered into...
AI drug discovery artificial intelligence Autoimmune Disease biologics Biomarkers biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development Drug Discovery EMA FDA fda approval FDA clearance Gene Therapy Healthcare Innovation healthcare technology immunology Immunotherapy Medical Devices MedTech Monoclonal Antibody Neurodegenerative Disease Neurology Oncology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 Phase 3 trial Precision Medicine Precision Oncology rare disease Regenerative Medicine targeted therapy
Beijing, China & Florence, Italy, September 3, 2026 Gan & Lee Pharmaceuticals and The Menarini Group have entered into...
LONDON, United Kingdom, July 13, 2026 The Alzheimer’s Association has announced the launch of the PROTECT-Cog Study (Prevention of...
SHANGHAI and HONG KONG, China, July 13, 2026 Antengene has announced the receipt of a USD 60 million upfront...
Rockville, Md. and Shanghai, January 18, 2026 — AbelZeta Pharma, Inc. announced that AstraZeneca has agreed to acquire AbelZeta’s...
